AstraZeneca reports mixed late-stage trial results with Ultomiris failure and Claudin 18.2 ADC success

AstraZeneca reports mixed clinical results as its rare disease drug Ultomiris failed to achieve statistical significance in a late-stage trial for adult stem cell transplant complications. Despite this setback, which follows other recent pipeline failures in 2026, AstraZeneca's experimental gastric cancer drug sonesitatug vedotin successfully improved overall survival in a Phase III trial. The company still plans pediatric regulatory filings for Ultomiris and targets $80 billion in annual revenue by 2030.

Ultomiris late-stage trial failure

• ▪Ultomiris did not achieve statistical significance for event-free survival at 26 weeks in adult patients, though it showed a trend toward benefit.
• ▪AstraZeneca's rare disease drug Ultomiris failed a late-stage trial in adult patients with haematopoietic stem cell transplant-associated thrombotic microangiopathy.
• ▪AstraZeneca is in ongoing discussions with global health authorities over potential next steps for the adult indication of Ultomiris.

Sonesitatug vedotin gastric cancer success

• ▪AstraZeneca's experimental gastric cancer drug sonesitatug vedotin met a key goal in a late-stage trial.
• ▪Sonesitatug vedotin showed a statistically significant and clinically meaningful improvement in overall survival in advanced gastric cancer patients.

AstraZeneca pipeline setbacks pattern

• ▪The failure of Ultomiris is the latest in a series of setbacks in 2026 that have fueled concerns about AstraZeneca's pipeline.
• ▪AstraZeneca experienced a failed pivotal heart-disease trial in July 2026, casting doubts over the drugmaker's trial design.
• ▪In May 2026, a United States regulatory panel rejected AstraZeneca's breast cancer drug camizestrant on trial design grounds.

Ultomiris pediatric trial results

• ▪AstraZeneca will advance regulatory filings for the use of Ultomiris in children.
• ▪In a pediatric trial, Ultomiris showed an overall survival rate of 87.2% at 26 weeks and 73.4% at 52 weeks.

AstraZeneca revenue growth strategy

• ▪AstraZeneca topped second-quarter profit expectations on strong demand for its cancer and rare disease therapies.
• ▪Ultomiris is already approved in the United States, the European Union, and Japan for treating certain rare blood disorders and neurological conditions.
• ▪AstraZeneca is counting on up to 20 new drug launches to help generate $80 billion in annual revenue by 2030.

2 sources